Functional polymorphisms in a candidate gene for atherothrombosis Unraveling the complex fabric of a polygenic phenotype**Editorials published in the Journal of the American College of Cardiologyreflect the views of the author and do not necessarily represent the views of JACCor the American College of Cardiology. by Loscalzo, Joseph
EDITORIAL COMMENT
Functional Polymorphisms
in a Candidate
Gene for Atherothrombosis
Unraveling the Complex
Fabric of a Polygenic Phenotype*
Joseph Loscalzo, MD, PHD, FACC
Boston, Massachusetts
Conventional risk factors for atherothrombotic vascular
disease account for approximately 50% of the total attrib-
utable risk burden. This fact has led to aggressive ap-
proaches to the identification of alternate determinants of
risk with mechanistic rationale. In this expanding era of the
human genome, epidemiologists in search of other risk
factors have been given a very large set of additional targets,
that is, polymorphisms or mutations throughout the ge-
nome. A polymorphism is a change in the sequence of a
normal or “wild-type” gene that is relatively abundant in a
population (i.e., 0.5% to 1%); by contrast, a mutation is a
change in the sequence of a wild-type gene that is less
common. Moreover, mutations often, and polymorphisms
on occasion, have been shown to affect the expression or
activity of a gene product, thus making their identification
important in discerning possible mechanistic determinants
of disease.
See pages 930 and 938
Atherothrombosis is a polygenic disease and is described
as a complex genetic trait; as opposed to sickle cell anemia
or familial hypercholesterolemia, for example, the disease
presentation or phenotype cannot be attributed to a muta-
tion or polymorphism in a single gene. Rather, mutations or
polymorphisms in multiple genes define atherothrombotic
propensity and phenotype, and these mutations or polymor-
phisms serve as the intellectual grist of genetic epidemiol-
ogists who strive to identify them and quantify the strength
of association between them and the risk of disease expres-
sion. In some cases, polymorphisms have been identified in
the sequence of genes that have no known function; in
others, polymorphisms have been identified in genes with
well-known functions, and, in some of these genes, poly-
morphic sequences have been shown to modify the level of
expression or the function of the gene product.
In this issue of the Journal, two polymorphisms in the
endothelial nitric oxide synthase (eNOS) gene, a gene
whose product is important for normal vascular function,
were analyzed in two different populations of individuals
with vascular disease or dysfunction. Nitric oxide (NO)
synthesized by eNOS from L-arginine is a principal medi-
ator of normal endothelial function (1). As a smooth muscle
relaxant, it promotes vasodilation; as a platelet inhibitor, it
prevents thrombosis; as an inhibitor of smooth muscle
migration and proliferation, it limits neointimal hyperplasia
after vascular injury; and as a scavenger of reactive oxygen
species, it modulates the inflammatory response by sup-
pressing oxidant stress-mediated transcriptional activation
of a variety of genes, including those that code for adhesion
molecules. As a result of these many effects, eNOS plays a
central role in maintaining normal vascular homeostasis and
is viewed as atheroprotective.
There are 10 polymorphisms that have been described in
the eNOS gene (2), three in the 5-flanking region of the
gene that are in linkage disequilibrium (T-1474A, A-922G,
and T-786C), two in the coding sequence (C774T and
G894T), and five in intronic regions. Among these base
changes, two have been shown to modify expression and
activity of the enzyme; the T-786C promoter polymor-
phism decreases transcription of the gene (3), and the
G894T polymorphism leads to a conservative amino acid
substitution of an aspartate for a glutamate residue, which is
believed to alter the conformation of the enzyme and
enhance its susceptibility to proteolytic cleavage (4). Thus,
these functional polymorphisms in a candidate gene are
prime targets for epidemiological study of possible associa-
tion with atherothrombotic vascular disease risk.
Early studies of these polymorphisms suggested that
there is, indeed, a greater prevalence of the less frequent
alleles in diseased (coronary and cerebrovascular) popula-
tions than in controls, especially in individuals with arterial
vasospasm (3,5–7). As the number of studies increased to
include broader, more ethnically diverse populations, how-
ever, these associations were not confirmed (8–10). Simi-
larly, two prior studies showed abnormal vascular function
in individuals bearing the G894T allele (11,12); however, a
third study failed to find such an association (13).
In two studies published in this issue of the Journal,
Caucasians (principally southern Europeans) were studied
to seek possible associations between the T-786C and
G894T polymorphisms and prevalent vascular disease or
dysfunction. In one study of 749 patients with angiographi-
cally defined coronary artery disease (CAD), Rossi et al.
(14) found that the T-786C polymorphism was significantly
more frequent than among 449 individuals without CAD;
subjects bearing the C allele had a significant increase in the
likelihood of having two- or three-vessel CAD than did
those who were homozygous for the T allele. No association
was found between the G894T polymorphism and the
presence of angiographically defined CAD.
In a second study of 137 essential hypertensive and 50
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normotensive subjects without clinical evidence of athero-
thrombotic vascular disease, Rossi et al. (15) found a greater
prevalence of the T-786C polymorphism among hyperten-
sive individuals with endothelial dysfunction than among
those without endothelial dysfunction; subjects bearing the
C allele had a significant reduction in the maximal forearm
blood flow response to acetylcholine compared with those
who were homozygous for the T allele. Importantly, while
there was a significant difference between hypertensives and
normotensives in their response to acetylcholine (confirm-
ing reports by others), there was no relationship between
T-786C allele frequency and forearm blood flow response
among normotensives. These results suggest that either the
T-786C allele is an important determinant of the hyperten-
sive diathesis or is a determinant of endothelial dysfunction
in individuals who have or are prone to hypertension for
other genetic reasons. Again, these investigators found no
association between the prevalence of the G894T polymor-
phism and the dysfunctional endothelial phenotype; how-
ever, they did detect a significant interaction between the
T-786C and G894T polymorphisms and the associated
endothelial dysfunction (15).
These observations confirm the potential functional im-
portance of these polymorphisms in atherothrombogenesis.
Owing to their relationship to abnormally low eNOS
activity, these polymorphisms lead to a state of relative NO
deficiency and promote endothelial dysfunction. Nitric ox-
ide deficiency is not only itself a manifestation of endothelial
dysfunction, but also limits the endothelial reserve needed to
combat the adverse effects of exogenous risk factors that lead
to a state of endothelial dysfunction. It is, therefore, not
surprising that, in the study of patients with CAD, smok-
ing, obesity, hypercholesterolemia, and older age were
additive to the effect of the T-786C polymorphism in
predicting the prevalence of atherothrombotic disease. A
similar result was recently reported between the T-786C
polymorphism and smoking as a risk for vascular abnormal-
ities in the cerebral circulation (16).
The quantitative strength of the association of the
T-786C polymorphism with the prevalence of CAD de-
serves comment. This association is weak, albeit statistically
significant, with an odds ratio of approximately 1.7. This
result suggests either that the association is not biologically
relevant or that this polymorphic allele alone is insufficient
to account for enhanced susceptibility to vascular disease or
dysfunction. Rather it requires other risk factors to manifest
adverse effects, that is, it is a disease-modifying allele. This
view is consonant with the polygenic nature of athero-
thrombosis in which multiple alleles interact with each
other and with environmental factors to produce the disease
phenotype.
There are multiple limitations of these two studies that
fall into study design and biological categories. In the study
of CAD (14), the use of two different control populations,
exclusion of some important risk factors from the logistic
regression model, the lack of correlative measures of eNOS
function, and the lack of a more quantitative measure of
atheroma burden are clear shortcomings. In the study of
endothelial function (15), the many significant baseline
differences between the hypertensive and normotensive
subjects and the lack of measurement of NO metabolites or
bioactivity are both important limitations. The lack of a
graded risk response to adverse allele abundance can either
be interpreted to mean that a threshold effect is all that is
required to promote disease expression, or that the associ-
ation is not biologically relevant. If the latter were the case,
one might interpret the results to mean that the eNOS
polymorphism is not itself related to disease progression but,
rather, genetically linked to another, as yet unidentified,
disease-determining genetic locus.
These observations taken together with previously pub-
lished results suggest that the eNOS polymorphisms do,
indeed, promote endothelial dysfunction and atherothrom-
bogenesis. To be sure, these data are small steps on a long
journey of discovery, but important, nonetheless, in gaining
a clear understanding of a complex pathobiology. In addi-
tion, these observations suggest that therapies tailored to
enhance endogenous NO production, to substitute exoge-
nous NO donors for limited endogenous stores, or to
decrease the oxidative inactivation of NO may prove bene-
ficial in individuals with eNOS polymorphisms that limit
the generation of bioactive, atheroprotective NO.
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